Overview
CLRB market data
Price History
CLRB price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$8.35 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.54 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -24,744.4% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $2.20 – $6.52 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $19.8M · P/B 1.26 · P/S 220.22.
Company News
Cellectar Biosciences 13G Filing Shows Balyasny Asset Management Reports 9.99% Stake In Co As Of June 30, 2026, Holding 798,382 Shares And WarrantsBenzinga · Aug 14, 2026, 4:17 PM
Cellectar Biosciences 13G Filing Shows StemPoint Capital Reports 9.99% Stake In Co As Of June 30, 2026, Holding 845,740 Shares Including Pre-Funded WarrantsBenzinga · Aug 14, 2026, 4:17 PM
Cellectar Biosciences 13G Filing Shows SilverArc Capital Reports 9.99% Stake In Co As Of June 30, 2026, Holding 851,285 Shares And WarrantsBenzinga · Aug 14, 2026, 4:16 PM
Cellectar Biosciences Q2 2026 Earnings Call TranscriptBenzinga · Aug 13, 2026, 1:19 PM
8-K filing — Cellectar Biosciences, Inc. (CLRB)SEC EDGAR · Aug 13, 2026, 11:25 AM
Cellectar Biosciences Q2 EPS $(0.57) Misses $(0.48) EstimateBenzinga · Aug 13, 2026, 11:03 AM
Cellectar Biosciences shares are trading lower. The company announced it published results from a Phase 1 dose-escalation study evaluating iopofosine I 131 in combination with low-dose dexamethasone in 31 patients with heavily pretreated relapsed/refractory multiple myeloma,Benzinga · Jul 15, 2026, 11:52 AM
Cellectar Biosciences Announces Publication Of Results From Phase 1 Dose-Escalation Study Evaluating Iopofosine I 131 In Combination With Low-Dose Dexamethasone In 31 Patients With Heavily Pretreated R/R MMBenzinga · Jul 15, 2026, 11:33 AM
Cellectar Biosciences To Highlight Efficacy Results From Phase 2 CLOVER WaM Clinical Trial Of Iopofosine I 131 To Treat r/r WM At 2026 ASCOBenzinga · Jun 1, 2026, 12:15 PM
Cellectar Biosciences Files Prospectus For Offering Of Up To 51.2M Shares Of Common Stock By Selling StockholdersBenzinga · May 19, 2026, 9:15 PM